Anupam Rasayan India Ltd (ANURAS) — Announcement | 28 September 2026 (2 announcements)

28 September 2026 · BSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

1Announcement🔴 High Importance Neutral📄 PDF

📢 Key Event

Anupam Rasayan completes Bliss GVS Pharma acquisition

🔄 What Changed

48.2% stake acquired; ₹299 crore paid; ₹300 crore term loan and ₹1,450 crore investor funding secured

🔮 What's Next

None

💡 Investor Takeaway

This acquisition completes Anupam Rasayan's backward, global, and forward integration strategy, creating a ₹4,000+ crore integrated pharma platform.

Anupam Rasayan India announced it has completed the acquisition of Bliss GVS Pharma for ₹299 per share, paying ₹299 crore for a 48.2% stake. The deal, funded by a ₹300 crore term loan and ₹1,450 crore from non-controlling investors including Bain Capital, marks the company's third strategic inorganic move to build an integrated global pharma platform. It expands Anupam Rasayan's presence into finished dosage formulations and strengthens its value chain integration from raw materials to finished products.

2Announcement Neutral📄 PDF

📢 Key Event

Trading window closes on October 1, 2026

💡 Investor Takeaway

Shareholders must plan trades around the announced blackout period.

Anupam Rasayan India Ltd announced that its trading window will close on October 1, 2026, and remain shut until 48 hours after the unaudited quarterly results for September 30, 2026 are released, as required by SEBI PIT Regulations.

📊 Stock Analysis — ANURAS ✨ Ask AI About This

About Anupam Rasayan India Ltd (ANURAS)

Chemicals · Chemicals · Listed on BSE

Market Cap: ₹13,509.81 CrP/E: 60.0ROE: 5.3%ROCE: 8.3%Div Yield: 0.13%

View full ANURAS stock details →

📡 Get AI alerts when ANURAS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ANURAS — Free

💡 Ask AI about this filing

"How does the ₹4,000+ crore pro-forma revenue break down across businesses?""What are the expected EBITDA margins post-acquisition?""How will the ₹1,450 crore investor funding impact future capital allocation?"

Ask AI Free →

📊 More ANURAS filings

🟡 Board Meeting — 23 September 2026Anupam Rasayan India announced execution of key security documents related to a proposed INR 300 cro...
🔴 Corporate Action — 21 September 2026Anupam Rasayan India announced the allotment of 14,500 senior secured rated unlisted redeemable non-...
🟡 Board Meeting — 19 September 2026Anupam Rasayan approved issuing up to 16,000 secured NCDs worth **₹160 crores** on September 19, 202...
🟡 Board Meeting — 19 September 2026Anupam Rasayan India approved up to 16,000 secured NCDs worth **₹160 crores** at 10.25% coupon via p...
🟡 Board Meeting — 17 September 2026Anupam Rasayan India approved execution of security documents for Mates Visa Consultancy's up to INR...

See all ANURAS filings →

🔥 Also filed on 28 September 2026

JSLJindal Stainless LtdCorporate Action GODREJPROPGodrej Properties LtdAnnouncement MANINFRAMan Infraconstruction LtdAnnouncement KPILKalpataru Projects International LtdAnnouncement SUNPHARMASun Pharmaceutical Industries LtdAnnouncement JUBLPHARMAJubilant Pharmova LtdCorporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ANURAS files new disclosures

Track ANURAS filings, board meetings, and corporate actions. Free email alerts at 5 PM.